Last reviewed · How we verify
Sativex
At a glance
| Generic name | Sativex |
|---|---|
| Also known as | Nabiximols, GW1000-02, THC/CBD spray, GW-1000-02, THC:CBD spray |
| Sponsor | Jazz Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Muscle Spasticity due to Multiple Sclerosis
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder (NA)
- Perceptions of Proposed Warnings for Cannabis Edibles Packaging (NA)
- Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis (NA)
- Preventing Impaired Driving Among Adolescents (NA)
- Neuroimaging of Adolescent Cannabis Use Treatment (NA)
- Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
- Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sativex CI brief — competitive landscape report
- Sativex updates RSS · CI watch RSS
- Jazz Pharmaceuticals portfolio CI